Production (Stage)
BioSyent Inc.
RX.V
TSX
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 5.62M | 5.31M | 5.23M | 5.29M | 5.24M |
Total Depreciation and Amortization | 646.10K | 587.50K | 218.50K | 227.60K | 219.90K |
Total Amortization of Deferred Charges | 13.30K | 10.10K | 130.60K | 119.40K | 121.20K |
Total Other Non-Cash Items | 109.70K | -69.70K | -564.80K | -538.30K | -576.70K |
Change in Net Operating Assets | -1.11M | 644.00K | -69.00K | -3.20M | 286.30K |
Cash from Operations | 5.11M | 6.31M | 4.94M | 1.90M | 5.29M |
Capital Expenditure | -50.40K | -38.80K | -46.60K | -49.20K | -46.10K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 3.60M | 3.05M | 1.12M | 4.09M | 215.40K |
Cash from Investing | 2.92M | 2.38M | 1.08M | 4.04M | 169.50K |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -185.70K | -183.20K | -180.80K | -178.40K | -176.10K |
Issuance of Common Stock | 308.90K | 250.40K | 155.10K | 104.90K | 66.90K |
Repurchase of Common Stock | -5.14M | -5.76M | -2.79M | -3.37M | -4.49M |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -1.52M | -1.52M | -1.50M | -1.47M | -1.45M |
Other Financing Activities | -56.70K | -59.20K | -61.60K | -64.00K | -66.30K |
Cash from Financing | -5.13M | -5.68M | -3.62M | -4.06M | -4.91M |
Foreign Exchange rate Adjustments | 3.10K | 3.70K | -130.40K | -57.00K | -46.40K |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 2.90M | 3.02M | 2.26M | 1.82M | 498.70K |